New coronavirus SARS-CoV-2 is capable to infect humans and cause a novel disease COVID-19. Aiming to understand a host genetic component of COVID-19, we focused on variants in genes encoding proteases and genes involved in innate immunity that could be important for susceptibility and resistance to SARS-CoV-2 infection.
Analysis of sequence data of coding regions of
FURIN, PLG, PRSS1, TMPRSS11a, MBL2
and
OAS1
genes in 143 unrelated individuals from Serbian population identified 22 variants with potential functional effect.
In silico
analyses (PolyPhen-2, SIFT, MutPred2 and Swiss-Pdb Viewer) predicted that 10 variants could impact the structure and/or function of proteins. These protein-altering variants (p.Gly146Ser in
FURIN
; p.Arg261His and p.Ala494Val in
PLG
; p.Asn54Lys in
PRSS1
; p.Arg52Cys, p.Gly54Asp and p.Gly57Glu in
MBL2
; p.Arg47Gln, p.Ile99Val and p.Arg130His in
OAS1
) may have predictive value for inter-individual differences in the response to the SARS-CoV-2 infection.
Next, we performed comparative population analysis for the same variants using extracted data from the 1000 Genomes project. Population genetic variability was assessed using delta MAF and Fst statistics. Our study pointed to 7 variants in
PLG, TMPRSS11a, MBL2
and
OAS1
genes with noticeable divergence in allelic frequencies between populations worldwide. Three of them, all in
MBL2
gene, were predicted to be damaging, making them the most promising population-specific markers related to SARS-CoV-2 infection.
Comparing allelic frequencies between Serbian and other populations, we found that the highest level of genetic divergence related to selected loci was observed with African, followed by East Asian, Central and South American and South Asian populations. When compared with European populations, the highest divergence was observed with Italian population.
In conclusion, we identified 4 variants in genes encoding proteases (
FURIN, PLG
and
PRSS1
) and 6 in genes involved in the innate immunity (
MBL2
and
OAS1
) that might be relevant for the host response to SARS-CoV-2 infection.